Polymorphisms Within the RET Proto-Oncogene and Risk of Sporadic Medullary Thyroid Carcinoma

被引:5
|
作者
Gemignani, Federica [1 ]
Romei, Cristina [2 ]
Ciampi, Raffaele [2 ]
Corrado, Alda [1 ]
Melaiu, Ombretta [1 ]
Figlioli, Gisella [3 ]
Bonotti, Alessandra [4 ]
Foddis, Rudy [4 ]
Cristaudo, Alfonso [4 ]
Pellegrini, Giovanni [5 ]
Vivaldi, Agnese [5 ]
Cipollini, Monica [1 ]
Landi, Stefano [1 ]
Elisei, Rossella [2 ]
机构
[1] Univ Pisa, Dept Biol, Via Dernal, Pisa 56100, Italy
[2] Univ Hosp Cisanello, Dept Clin & Expt Med, Endocrine Unit, Pisa, Italy
[3] FIRC Inst Mol Oncol, IFOM, Milan, Italy
[4] Hosp Cisanello, Dept Translat Res & New Technol Med & Surg, Pisa, Italy
[5] Univ Hosp Cisanello, Lab Clin Chem Anal, Operat Unit, Pisa, Italy
关键词
RET; polymorphisms; sporadic medullary thyroid carcinoma; association study; haplotype; MOLECULAR CHARACTERIZATION; TYROSINE KINASE; GENE; REARRANGEMENTS; ASSOCIATION; MANAGEMENT; CHERNOBYL; VARIANTS; G691S; MODEL;
D O I
10.1089/thy.2019.0352
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Sporadic medullary thyroid carcinoma (sMTC) is an uncommon neoplasia arising from the calcitonin-producing parafollicular cells of the thyroid. Previous studies evaluated whether single nucleotide polymorphisms (SNPs) within RET (a pivotal proto-oncogene for this disease) are associated with the risk for developing sMTC, but the results are inconclusive. Methods: In this work, we evaluated the association of RET-SNPs c.74-126G>T (rs2565206), p.Gly691Ser (rs1799939, G>A), p.Leu769 = (rs1800861, G>T), p.Ser836 = (rs1800862, C>T), and p.Ser904 = (rs1800863, C>G) (listed in the order of their chromosomal location) with sMTC. This is one of the largest case-control association studies carried out on sMTC, including 585 sMTC cases (negative for germline mutations within RET), 1529 patients affected by sporadic nonmedullary thyroid carcinoma (sNMTC), and 989 healthy controls, from central and southern Italy and collected in the period 2000-2017. Results: sNMTC patients showed similar genotype and allele frequencies compared with healthy controls. On the other hand, among sMTC patients, the T-allele of p.Leu769 = was less frequent (OR = 0.70 [CI 0.58-0.84], p = 1.9 x 10(-4)) and rare homozygotes TT showed an OR = 0.32 ([CI 0.17-0.60], p = 2.3 x 10(-4)). Moreover, a statistically significant excess of the haplotype 2 (characterized by the alleles T-G-G-C-C of the listed SNPs) was observed (p = 3.9 x 10(-3)). The SNPs were not associated with the expression of RET mRNA, that is, they did not exert an effect in cis as quantitative trait locus (cis-eQTL). However, a strong eQTL association was found for p.Leu769 = and the neighboring gene CSGALNACT2 (p = 9.3 x 10(-50); effect-size = -0.65), whose function in cancer is unknown. Conclusions: This study shows that specific RET haplotypes, in particular haplotype 2 and the T-allele of p.Leu769 = , are associated with a reduced risk of sMTC in Italians.
引用
收藏
页码:1579 / 1588
页数:10
相关论文
共 50 条
  • [41] RET proto-oncogene and thyroid cancer
    Paul Komminoth
    Endocrine Pathology, 1997, 8 : 235 - 239
  • [42] RET proto-oncogene and thyroid cancer
    Komminoth, P
    ENDOCRINE PATHOLOGY, 1997, 8 (03) : 235 - 239
  • [43] Novel point mutation in exon 10 of the RET proto-oncogene in a family with medullary thyroid carcinoma
    Oriola, J
    Páramo, C
    Halperin, I
    García-Mayor, RV
    Rivera-Fillat, F
    AMERICAN JOURNAL OF MEDICAL GENETICS, 1998, 78 (03): : 271 - 273
  • [44] The RET proto-oncogene in medullary and papillary thyroid carcinoma Molecular features, pathophysiology and clinical implications
    Paul Komminoth
    Virchows Archiv, 1997, 431 : 1 - 9
  • [45] Identification of a novel somatic mutation in the RET proto oncogene in a patient with sporadic medullary thyroid carcinoma
    MatiasGuiu, X
    Lagarda, E
    Calaf, M
    Azpiroz, A
    DeLeiva, A
    Prat, J
    Baiget, M
    HUMAN MUTATION, 1997, 9 (05) : 476 - 476
  • [46] RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma
    Marsh, DJ
    Mulligan, LM
    Eng, C
    HORMONE RESEARCH, 1997, 47 (4-6) : 168 - 178
  • [47] The RET proto-oncogene in medullary and papillary thyroid carcinoma - Molecular features, pathophysiology and clinical implications
    Komminoth, P
    VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY, 1997, 431 (01): : 1 - 9
  • [48] Ret-proto-oncogene analysis in medullary thyroid carcinoma
    O'Keeffe, DA
    Hill, ADK
    Sheahan, K
    Ryan, F
    Barton, D
    Fitzgerald, RJ
    McDermott, EW
    O'Higgins, NJ
    IRISH JOURNAL OF MEDICAL SCIENCE, 1998, 167 (04) : 226 - 230
  • [49] Ret-proto-oncogene analysis in medullary thyroid carcinoma
    D. A. O’Keeffe
    A. D. K. Hill
    E. W. McDermott
    N. J. O’Higgins
    K. Sheahan
    F. Ryan
    D. Barton
    R. J. Fitzgerald
    Irish Journal of Medical Science, 1998, 167 : 226 - 230
  • [50] A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma
    Romei, Cristina
    Ciampi, Raffaele
    Elise, Rossella
    NATURE REVIEWS ENDOCRINOLOGY, 2016, 12 (04) : 192 - 202